Cerenovus—a neurovascular firm that forms part of Johnson & Johnson Medical Devices Companies—has announced the launch of Emboguard, its next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischaemic stroke.
Emboguard is designed to optimise removal of blood clots by controlling blood flow locally during mechanical thrombectomy procedures. Balloon guide catheters increase first pass recanalisation, reduce procedure time, and reduce the odds of clot fragments breaking off and causing distal emboli, according to a Cerenovus press release, which also details that distal emboli in an endovascular procedure can result in new ischaemic events.
“Without timely and effective treatment of stroke, patients can suffer from lifelong disability or dependency,” said David Fiorella (Stony Brook University Hospital, New York, USA). “The benefits of balloon guide catheters are becoming increasingly recognised for their ability to maximise patient outcomes. By adding this innovation to their stroke solutions portfolio, Cerenovus will be arming physicians with the tools they need to better serve our patients, potentially increasing the chances to live a functional and fulfilling life post-stroke.”
Emboguard is the latest addition to Cerenovus Stroke Solutions—a suite of technologies designed with compatibility in mind to assist physicians in performing mechanical thrombectomy procedures. Launched in 2020, it now includes the Embotrap III revascularisation device, the Prowler Ex microcatheter, and the Cerenovus large bore catheter as well as both the Emboguard balloon guide catheter and the Cerebase guide sheath.
The Emboguard balloon guide catheter is set to debut for the first time at the ongoing International Stroke Conference (ISC 2022; 9–11 February, New Orleans, USA).